The presence of maternal antibodies is one of the main causes of measles vaccine failure.
To evaluate the interference of passively acquired antibodies with vaccine efficacy …

Recombinant modified vaccinia virus Ankara (MVA), encoding the measles virus (MV) fusion
(F) and hemagglutinin (H)(MVA-FH) glycoproteins, was evaluated in an MV vaccination …

We have used vaccinia-measles recombinant viruses to study vaccination in the presence of
pre-existing antibody. When mice were vaccinated with recombinants expressing either the …

The neutralization capacity of sera from Luxembourgian adolescent vaccinees and from
Nigerian women with measles‐induced immunity to a number of measles virus strains was …

A group of 40 kindergarten and first-grade school children were immunized with three doses
of inactivated measles virus vaccine, or an equivalent placebo, at 0, 1, and 4 weeks as part …

Maternal antibody prevents the use of live, attenuated measles vaccine (LAV) before 6–9
months of age, but vaccinated 6-month-old infants can mount a T cell response. An infant …

A nation‐wide measles outbreak occurred in 1988 in Taiwan. A retrospective cohort study
was conducted to define the protective titre of measles neutralising (NT) antibody. Paired …

Further-attenuated strains of measles virus may be distinguished from virulent strains by the
following characteristics. Unlike virulent strains, attenuated strains of measles virus can be …

Early or low dose antigen exposure can prime the immune system for subsequent
responses; the so-called “prime-boost” effect. In the context of a Sudanese measles vaccine …

A vaccine that is effective in the presence of maternally derived virus neutralizing antibodies
and can be administered successfully at an early age, would be favoured over the presently …